Form 4: ADMA Biologics Director Young Kwon Sells 60,000 Shares

Director Young Kwon of ADMA Biologics, Inc. sold 60,000 shares of common stock at an average price of $18.26 on August 23, 2024.

Summary

• On August 23, 2024, Young Kwon, a director of ADMA Biologics, Inc., sold 60,000 shares of the company's common stock.
• The shares were sold at a weighted average price of $18.26, with individual transactions ranging from $18.25 to $18.27.
• Following the transaction, Kwon directly owns 241,441 shares of ADMA Biologics, Inc.
• This includes 12,020 restricted stock units (RSUs) granted on February 26, 2024, which will vest on February 26, 2025, contingent upon continued service.
• It also includes 229,421 shares of common stock.
• A Limited Power of Attorney was granted to Adam S. Grossman and Michael A. Goldstein to handle Section 16(a) reporting.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when a company insider, such as a director, buys or sells shares of their company's stock. It provides transparency to the market regarding insider transactions.

Comparison to Industry Standards

• Insider selling is a common occurrence in publicly traded companies.
• The significance of this sale would typically be assessed in relation to the director's overall holdings, the reasons for the sale (which are not disclosed in this filing), and in comparison to insider trading activity at peer companies such as CSL Behring, Takeda Pharmaceutical, and Grifols.

Stakeholder Impact

• The stock sale may have a minor impact on shareholder sentiment, depending on how the market interprets the director's decision to sell shares.
• The sale represents a reduction in the director's direct exposure to the company's stock performance.

Key Dates